What is heart failure?

Heart failure is a clinical syndrome in which the heart cannot pump enough blood to meet the body's demands, or can only do so at elevated filling pressures. It is not the heart stopping. The heart is still beating. It is failing to function at adequate capacity. Heart failure has two main types: reduced ejection fraction (HFrEF), where the pump function is impaired, and preserved ejection fraction (HFpEF), where the pump function is normal but the heart cannot fill normally.

What are the symptoms of heart failure in men?

Shortness of breath, particularly with exertion or when lying flat. Leg swelling, typically worse at the end of the day. Fatigue disproportionate to activity. Reduced exercise tolerance compared to previous baseline. Waking at night breathless. Some men with early heart failure experience only fatigue and reduced exercise capacity without obvious fluid symptoms.

Can heart failure be reversed?

It depends on the type and the cause. Some forms of heart failure are reversible, particularly those caused by uncontrolled hypertension, thyroid disease, alcohol, or certain medications. When the underlying cause is treated, cardiac function can partially or fully recover. Most forms of established HFrEF improve significantly with guideline-directed medical therapy but do not fully normalize.

What causes heart failure with preserved ejection fraction?

HFpEF is characterized by a stiff ventricle that cannot relax adequately during diastole, producing elevated filling pressures despite normal pumping function. The primary drivers are hypertension, obesity, diabetes, and atrial fibrillation, all of which promote myocardial fibrosis and impaired lusitropy. Unlike HFrEF, where the myocardium is dilated and weak, in HFpEF the myocardium is thick and stiff. SGLT2 inhibitors are the first class of medication to demonstrate mortality benefit specifically in HFpEF.

How is heart failure diagnosed?

Diagnosis combines clinical assessment with objective evidence of structural or functional cardiac abnormality. Echocardiography is the primary imaging tool, evaluating ejection fraction, ventricular dimensions, diastolic function parameters, and valvular disease. BNP or NT-proBNP levels confirm hemodynamic stress on the heart. Elevated filling pressures on exercise testing can unmask HFpEF in patients with exertional dyspnea but normal resting echocardiography.

The Vascular Clock

Heart Failure Is Not Your Heart Stopping. Here Is What It Actually Means.

Heart failure does not mean the heart has stopped. A cardiologist explains both types, why men with preserved EF often go undiagnosed, and what to look for.

Job Mogire, MD, FACP, FACC · Medically reviewed June 14, 2026

The name causes the most common misunderstanding in cardiology. Heart failure does not mean the heart has stopped, or is about to stop. It means the heart is not functioning at adequate capacity to meet the body’s circulatory demands. The heart is still beating; it is failing to deliver sufficient output, or can only do so at filling pressures high enough to drive fluid into the lungs and peripheral tissues, producing the symptoms that eventually bring a man to a doctor’s office.

Heart failure affects approximately 6.2 million Americans, and according to AHA Heart Disease and Stroke Statistics 2024, prevalence is rising, driven substantially by the aging of the population combined with increasing rates of hypertension, obesity, and type 2 diabetes. Men develop heart failure at earlier ages than women, in large part because of earlier-onset coronary artery disease and higher rates of prior myocardial infarction. The five-year mortality remains above 50 percent across all subtypes, a number that surprises most patients when they first hear it. 5 / Solid

The Mechanism

To understand what goes wrong in heart failure, you need to understand what the heart is doing under normal conditions. With each beat, the left ventricle contracts (systole), ejecting blood into the aorta. It then relaxes (diastole), filling from the pulmonary veins through the left atrium. The ratio of blood ejected to total volume present is the ejection fraction. A healthy ventricle ejects 55 to 65 percent of the blood it contains per beat.

When cardiac output falls, even slightly, the body initiates compensatory responses that in the short term preserve perfusion but in the long term accelerate cardiac deterioration. The Frank-Starling mechanism is the first line of compensation: the more the ventricle is stretched by increased filling volume, the harder it contracts. This works within limits. Beyond a threshold, additional stretching no longer improves output and begins to worsen it. The ventricle dilates to accommodate increasing volumes, but the dilated chamber requires more oxygen to generate the same contractile force, increasing metabolic demand while reducing efficiency.

Neurohormonal activation runs in parallel. Reduced cardiac output triggers two major systems. The renin-angiotensin-aldosterone system (RAAS) is activated when renal perfusion falls, causing sodium and water retention to increase blood volume and venous pressure. This initially raises cardiac filling and output via the Frank-Starling mechanism but ultimately overloads an already struggling heart. The sympathetic nervous system (SNS) simultaneously releases catecholamines that increase heart rate and contractility in the short term. Chronically elevated catecholamines, however, are directly cardiotoxic. They promote myocyte apoptosis, fibrosis, and further remodeling. This is why blocking both systems, with beta-blockers and RAAS inhibitors, is the mechanistic foundation of heart failure pharmacotherapy.

Cardiac remodeling is the structural consequence of these sustained stresses. In HFrEF, the ventricle typically undergoes eccentric hypertrophy: volume overload stretches myocytes longitudinally, the chamber dilates, and the wall thins relative to cavity size, producing the classic “dilated cardiomyopathy” appearance on echocardiogram. In HFpEF, the pattern is concentric hypertrophy: pressure overload from chronic hypertension stimulates myocyte thickening in the radial direction, the wall becomes thicker relative to cavity size, and the overall chamber volume is normal or reduced. The concentric ventricle is stiffer. It cannot relax normally.

Diastolic dysfunction, the central pathology of HFpEF, operates at the cellular level through two mechanisms. The first involves titin, a giant structural protein that acts as a molecular spring within the sarcomere. In HFpEF, titin undergoes hypophosphorylation, reducing its compliance and making it stiffer. This increases the passive force required to stretch the myocyte during filling. The second mechanism is impaired calcium handling: in a normal relaxation cycle, calcium is rapidly re-sequestered into the sarcoplasmic reticulum by the SERCA2a pump, allowing the myocyte to lengthen. In HFpEF, SERCA2a activity is reduced, calcium clearance is delayed, and the cell remains in a partial contraction state during diastole. The aggregate effect of these cellular changes is a ventricle that resists filling, requires abnormally elevated pressures to fill to adequate volume, and transmits those pressures backward into the pulmonary circulation, producing the breathlessness that is HFpEF’s signature symptom.

What the Evidence Shows

The evidence base for HFrEF treatment is among the strongest in cardiovascular medicine, built across multiple decades and tens of thousands of patients. The foundation was established with ACE inhibitors: the CONSENSUS trial (1987) and SOLVD-Treatment trial (1991) demonstrated mortality reductions of 27 and 16 percent respectively in patients with reduced ejection fraction. Beta-blockade was confirmed in the MERIT-HF trial (1999), which randomized 3,991 patients and showed a 34 percent relative risk reduction in all-cause mortality with metoprolol succinate compared to placebo.

The most significant recent advance in HFrEF was the PARADIGM-HF trial, published in the New England Journal of Medicine in 2014 (McMurray et al., N Engl J Med 2014;371:993-1004). This trial randomized 8,442 patients with HFrEF and ejection fraction below 40 percent to either enalapril or sacubitril-valsartan (an ARNI, angiotensin receptor-neprilysin inhibitor). The primary composite endpoint of cardiovascular death or heart failure hospitalization occurred in 21.8 percent of the sacubitril-valsartan group versus 26.5 percent of the enalapril group, a hazard ratio of 0.80 (95% CI 0.73-0.87, p < 0.001). Cardiovascular mortality alone was reduced by 20 percent. This trial reshaped guidelines globally. Sacubitril-valsartan is now a first-line agent for HFrEF. 5 / Solid

SGLT2 inhibitors added a fourth pillar. The EMPEROR-Reduced trial (Packer et al., N Engl J Med 2020;383:1413-1424) randomized 3,730 patients with HFrEF to empagliflozin or placebo, on top of background guideline-directed therapy. The primary composite of cardiovascular death or heart failure hospitalization was reduced by 25 percent (hazard ratio 0.75, 95% CI 0.65-0.86, p < 0.001). Total heart failure hospitalizations, including recurrent events, were reduced by 30 percent. The benefit was consistent regardless of whether patients had diabetes. SGLT2 inhibitors are now Class I recommended in all HFrEF patients. The mechanism appears to involve myocardial energetics, preload and afterload reduction via osmotic diuresis, and direct anti-inflammatory and anti-fibrotic effects at the myocardial level, though the precise weighting of these mechanisms remains an active area of investigation.

The HFpEF evidence base is considerably weaker, and this contrast is clinically important. The I-PRESERVE trial (Massie et al., N Engl J Med 2008;359:2456-2467) randomized 4,128 patients with HFpEF to irbesartan or placebo and found no significant difference in the primary composite of mortality or cardiovascular hospitalization (hazard ratio 0.95, 95% CI 0.86-1.05, p = 0.35). The TOPCAT trial of spironolactone in HFpEF (Pitt et al., N Engl J Med 2014;370:1383-1392) produced a primary outcome that was not statistically significant overall (hazard ratio 0.89, p = 0.14), though post-hoc analyses suggested regional differences in outcomes that generated considerable methodological debate. Neither trial produced a definitive treatment. Until recently, HFpEF had no mortality-reducing therapy with solid trial evidence. 5 / Solid

That changed with EMPEROR-Preserved (Anker et al., N Engl J Med 2021;385:1451-1461), which randomized 5,988 patients with HFpEF to empagliflozin or placebo. The primary composite of cardiovascular death or heart failure hospitalization was reduced by 21 percent (hazard ratio 0.79, 95% CI 0.69-0.90, p < 0.001). This was driven primarily by reduction in heart failure hospitalizations rather than cardiovascular mortality. Empagliflozin became the first agent with a positive randomized controlled trial in HFpEF, and this result was subsequently supported by DELIVER (Solomon et al., N Engl J Med 2022;387:1089-1098) with dapagliflozin, which found a 18 percent relative risk reduction in the primary composite (hazard ratio 0.82, 95% CI 0.73-0.92, p < 0.001). 5 / Solid

For middle-aged men with metabolic syndrome and HFpEF, these trials matter directly: SGLT2 inhibitors are now guideline-supported in HFpEF and provide benefit independent of diabetes status. They are also used for glucose lowering, kidney protection, and cardiovascular risk reduction. A man in his fifties with hypertension, insulin resistance, and early diastolic dysfunction may be a candidate for this class for more than one indication.

Cardiologist's Note

The pattern I see most often in men who come to me in their late forties and fifties is what I call the “normal echo” problem. The patient had an echocardiogram ordered by another physician because of symptoms, shortness of breath on the stairs, fatigue that does not resolve with rest, ankle swelling at the end of the day. The report comes back: ejection fraction 58 percent, no wall motion abnormalities. The physician tells the patient his heart is fine. The patient is relieved. The symptoms continue.

What was often not assessed, or not communicated, is diastolic function. A complete diastolic assessment requires measurement of the E/e’ ratio (the ratio of mitral inflow velocity to tissue Doppler velocity at the annulus), left atrial volume index, tricuspid regurgitation velocity (to estimate pulmonary pressures), and the E/A ratio at the mitral valve. When these are present and graded, you can often identify Grade I or Grade II diastolic dysfunction in a patient who otherwise appears to have a structurally normal heart. Grade II diastolic dysfunction with symptoms is heart failure with preserved ejection fraction. It is not a normal echocardiogram.

The metabolic man is particularly susceptible. Central adiposity, insulin resistance, and chronically elevated blood pressure combine to produce concentric left ventricular hypertrophy over years, before any symptoms appear. By the time a man notices his exercise tolerance has fallen, the structural remodeling has often been underway for a decade. This is why I ask every middle-aged male patient with hypertension and metabolic syndrome about their exercise tolerance trajectory. Not their current level, their trajectory. A man who could walk briskly for forty minutes five years ago and now gets winded after fifteen minutes on flat ground has had a meaningful change that needs evaluation, regardless of what any single test shows in isolation.

One diagnostic scenario worth flagging explicitly: HFpEF often presents with normal resting findings and becomes apparent only under hemodynamic stress. Exercise stress echocardiography can unmask elevated filling pressures that are not present at rest. In a patient with compelling symptoms but a normal resting echo, this is a reasonable next step before concluding that the heart is not the problem. I have diagnosed HFpEF this way in men who had been told for two or three years that their cardiac workup was negative.

The Difference Between Heart Failure and a Heart Attack

These two terms are confused frequently enough that a direct comparison is warranted. A heart attack (myocardial infarction) is an acute event: a coronary artery is occluded, usually by plaque rupture and thrombus, and the myocardium supplied by that artery begins to die within minutes. It presents acutely with chest pain, diaphoresis, and electrocardiographic changes. It is a medical emergency requiring immediate reperfusion.

Heart failure is a chronic syndrome, not an acute event. It develops over months to years as cardiac function gradually deteriorates. A man does not “have a heart failure” the way he has a heart attack. He develops heart failure. That said, a heart attack is one of the most common causes of HFrEF: the area of myocardium killed by infarction does not recover contractile function, and if the area is large enough, the overall ejection fraction falls below 40 percent. In this scenario, the heart attack was the precipitant and the resulting HFrEF is the chronic condition that then requires long-term management.

Heart failure can also worsen acutely, producing “acute decompensated heart failure,” in which fluid accumulates rapidly and the patient becomes severely short of breath. This is the presentation that brings most patients to emergency departments. It is a decompensation of chronic disease, not the same phenomenon as a heart attack, though both are medical emergencies.

Understanding this distinction matters for symptom recognition. The gradual onset of heart failure symptoms, exertional breathlessness that worsens over months, progressive leg swelling, declining exercise tolerance, is frequently attributed to aging, deconditioning, or weight gain. Men in particular tend to accommodate declining function without seeking evaluation, raising their threshold for what is acceptable and what constitutes a symptom worth reporting. By the time heart failure is diagnosed clinically, the structural changes that produced it have typically been developing for years.

What to Do This Week

Examine your exercise tolerance trajectory over the past three to five years, not just your current level. If you could climb two flights of stairs without stopping four years ago and now stop at one, that change requires explanation. Deconditioning alone rarely produces that rate of decline in a man who is otherwise active. Ask your physician about it directly, framed as a trajectory question rather than a current-state question.
If you have had an echocardiogram reported as “normal,” confirm that diastolic function was specifically assessed. Ask your physician whether your report included E/e’ ratio, left atrial volume index, and diastolic grade. If those parameters are absent from the report, the echocardiogram did not fully evaluate you for HFpEF, regardless of what the ejection fraction showed.
Pursue blood pressure control to below 130/80 mmHg. This is the most important modifiable intervention for preventing HFpEF in the metabolic phenotype. The 2017 ACC/AHA hypertension guidelines set this threshold based on the SPRINT trial data showing cardiovascular event reduction at systolic targets below 120 mmHg in high-risk patients. The structural remodeling that produces HFpEF is largely hypertension-driven. Controlling blood pressure earlier and more aggressively interrupts that pathway before irreversible changes occur.
If you have type 2 diabetes or are considered for pharmacotherapy for metabolic or cardiovascular risk, discuss SGLT2 inhibitors with your physician. This drug class reduces heart failure hospitalizations in both HFrEF and HFpEF, in addition to their glucose-lowering and kidney-protective effects. For a man with hypertension, insulin resistance, and early diastolic dysfunction, the risk-benefit profile of this class is favorable across multiple organ systems simultaneously.
Know which symptoms to treat as urgent. Sudden severe shortness of breath at rest, particularly at night, that forces you to sit upright to breathe is a potential sign of acute decompensated heart failure and requires emergency evaluation, not a scheduled appointment. Rapid unexplained weight gain of more than three pounds in 24 hours or five pounds in a week may indicate fluid retention from worsening heart failure in someone already diagnosed. These are not symptoms to manage with watchful waiting.

Men in their forties and fifties who carry the metabolic phenotype, central obesity, elevated blood pressure, impaired fasting glucose, and a family history of cardiovascular disease, sit in the highest-risk group for developing HFpEF over the next decade. The syndrome is not inevitable. The pathway to it runs through years of modifiable exposures. The clinical window for interrupting that pathway closes slowly but it does close: concentric hypertrophy that has been present for fifteen years produces fibrosis that does not reverse with blood pressure control alone. The time to act is before the symptoms become the presenting complaint, and that means understanding what heart failure is before a cardiologist is the one explaining it.

The Signal Check is fifteen questions mapping the cardiovascular risk pattern across the physiological domains most commonly missed in standard screenings. It produces a specific starting point for your next clinical conversation.

Start with the gap between how you appear and what your body is doing.

Take the Signal Check

Did this land?

The conversation

Join the men working through this in the open.